Company intelligence / Profile preview
Clearmind Medicine
- Ownership
- Public · CMND
- Development stage
- Phase 1
Overview
Clearmind Medicine has initiated a multi-site Phase I/IIa clinical trial of its lead candidate, CMND‑100, an oral MEAI-based drug targeting alcohol use disorder. The trial evaluates safety, tolerability, and pharmacokinetics at leading institutions including Johns Hopkins University and Yale School of Medicine. The company has also secured exclusive rights to novel psychedelic compounds for PTSD from Hebrew University. No published efficacy results yet; the company’s pipeline remains in early-stage human studies.
- Therapeutic areas
- Psychiatry
- Modalities
- Psychedelic-derived small molecules (notably MEAI/5-Methoxy-2-aminoindane)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $3M
- Total revenue
- $0
- Enterprise value
- $-11.2M
Beyond the preview
Go deeper on Clearmind Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clearmind Medicine.